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Summary
Objective: The anabolic cytokine insulin-like growth factor I (IGF-I) stimulates chondrocyte synthesis of matrix macromolecules and several
lines of evidence suggest that it has a major role in maintaining articular cartilage and possibly in cartilage repair. Despite the apparent
importance of IGF-I in articular cartilage metabolism and its potential importance in joint diseases, little is known about the regulation of IGF-I
activity within the tissue. Insulin-like growth factor binding proteins (IGFBPs) bind IGF-I and can modify its activity. At least three IGFBPs are
expressed by chondrocytes: IGFBP-3, -4 and -5. Localization of IGFPBs in the articular cartilage extracellular matrix (ECM) could create
reservoirs of IGF-I within the articular cartilage ECM and thereby regulate local IGF-I levels. We hypothesized that ECM molecules bind and
concentrate IGFPBs in the pericellular/territorial matrix.
Design: Semi-quantitative immunohistological measures of co-localization were used to compare the spatial distribution of IGFBP-3, -4, and
-5 with the distributions of three peri-cellularly-enriched matrix molecules fibronectin, tenascin-C, and type VI collagen in osteoarthritic and
non-osteoarthritic human articular cartilage. Purified proteins were used in an agarose diffusion assay to compare IGFBP-3 binding to the
same three matrix proteins.
Results: IGFBP-3 associated with fibronectin in the pericellular/territorial matrix (∼40% co-localization) but not with tenascin-C, or type VI
collagen (∼6% and ∼15% co-localization respectively, P<0.05). Neither IGFBP-4, nor IGFBP-5 were associated with any of the three ECM
proteins (P<0.05). In agarose diffusion assays IGFBP-3 interacted with fibronectin and heparan sulfate proteoglycan but not with type VI
collagen or tenascin-C.
Conclusions: Direct binding between purified IGFBP-3 and fibronectin and the strong co-localization the two proteins in the cartilage matrix
support the hypothesis that IGFPB-3 and fibronectin help regulate local IGF-I levels. © 2002 Published by Elsevier Science Ltd on behalf
of OsteoArthritis Research Society InternationalReceived 19 April 2000; final revision accepted 19 February
2002.
Address correspondence to Joseph A. Buckwalter, 01013
Pappajohn Pavilion, Department of Orthopaedics, University of
Iowa College of Medicine, Iowa City, IA 52242. Tel: (319) 356-
2595; Fax: (319) 356-8999; E-mail: joseph-buckwalter@uiowa.eduIntroduction
To maintain the structure, composition and mechanical
properties of articular cartilage, chondrocytes must continu-
ally replace degraded matrix macromolecules. Insulin-like
growth factor I (IGF-I), an anabolic cytokine produced by
articular cartilage chondrocytes, induces the synthesis of
aggrecan and type II collagen, two major components of
the articular cartilage extracellular matrix (ECM)1–4. Recent
studies show that declining IGF-I sensitivity is associated
with the age-related loss of synthetic activities of chondro-
cytes and that an impaired IGF-I response is characteristic
of osteoarthritic cartilage5–11. These observations strongly
suggest that IGF-I stimulation of chondrocyte synthetic
activity is critical for the maintenance of articular cartilage
and that disturbances in IGF-I-mediated chondrocyte
anabolic activity may contribute to degeneration of the
tissue. Although the effects of IGF-I on chondrocyte activity
have been well described, the regulation of IGF-I concen-
tration and activity in articular cartilage remains poorly
understood.556Cellular responsiveness to IGF-I depends on the density
of type I IGF-I receptors (IGFRs) on the cell surface, and
on intracellular signal transduction pathways, however,
the levels of IGF-I available for receptor binding are
strongly affected by extracellular IGF-I binding proteins
(IGFBPs)12–14. These proteins bind IGF-I with an affinity
comparable to that of the IGF-I receptor (Kd=1×10−9
M−1)15,16. Because IGFBP-bound IGF-I does not bind to
IGFRs, the effective concentration of IGF-I in a solution is
lowered by the presence of binding proteins. Some inves-
tigators have reported that the addition of IGFBPs to cell
cultures inhibits IGF-I responses5,17–20. However, others
have shown potentiation of IGF-I activity by IGFPBs, due
perhaps to the extended half-life of IGFBP-bound IGF-I, as
well as direct effects of IGFBPs on cell anabolic activities
such as glucose uptake12,16,21–24. IGFBP expression is
subject to regulation by a number of factors including
prostaglandins, interleukin-1 and tumor necrosis factor
25–30. The half life of secreted IGFBPs may also
be regulated by extracellular proteolysis31–35. These
investigations show that IGFBPs can play varied roles in
regulating cell anabolic activities.
At least 4 IGFBPs are expressed in human articular
cartilage, these include IGFBP-2, -3, -4, and -514. Some
may form ternary complexes that include IGF-I, IGFBPs
and ECM molecules that bind IGFBPs36,37. Interactions
among the molecules in these complexes may provide a
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Human tibial plateau cartilage was harvested from five
patients (aged 37, 52, 67, 77, 84 years) that had undergone
total joint replacement for degenerative joint disease (osteo-
arthritic samples). Non-osteoarthritic samples were from
tibial plateaus of four patients aged 6 months, 14 years, 28
years, and 47 years. The six-month old sample was from an
above-knee amputation for treatment of a mid tibial defect
and the remaining samples were from limbs amputated sub-
sequent to a diagnosis of osteosarcoma. Samples were
taken from the central regions of the plateaus and were
immediately cryoembedded. Three 10 m-thick frozen sec-
tions were placed on gelatin-coated slides and fixed for 5 min
in 3.5% paraformaldehyde freshly prepared in phosphate
buffered saline (PBS). The sections were washed repeatedly
with PBS with 0.1% Tween-20 (PBST) and were digested
with 1800 /ml bovine testicular hyluronidase (Sigma) in
0.1 M sodium acetate pH 6.0 for 30 min at room temperature
to improve accessibility of tissue antigens. After washing in
PBST the sections were blocked with 1% bovine serum
albumin (Sigma) in PBST for 30 min. Mouse monoclonal
antibodies against fibronectin (clone HFN7.1, Developmental
Studies Hybridoma Bank), type VI collagen (clone 5C6,
Developmental Studies Hybridoma Bank), and tenascin-C
(Clone EB2, ICN), were diluted to ∼2 g/ml IgG in PBST.
Rabbit anti-IGFBP polyclonal antibodies including antihuman
IGFBP-3, antihuman IGFBP-4, and antihuman IGFBP-5 (Up-
state Biotechnology) were then diluted 1:50 in the mono-
clonal antibody solutions. The sections were incubated with
primary antibodies overnight at 4°C then washed in PBST
and blocked in 10% normal goat serum for 30 min before the
addition of secondary antibodies. Secondary antibodies were
diluted 1:400 and consisted of a goat antimouse Cy2 conju-
gate and a goat antirabbit Cy5 conjugate (Jackson Immu-
noresearch). The slides were incubated for 1 h at ambient
temperature. Isotype controls, in which purified mouse IgG
(diluted to 2 g/ml) or normal rabbit serum (diluted 1:50)
replaced the primary antibodies, were included on every
slide. These were consistently negative. Furthermore, the
specificity of the polyclonal antibodies was demonstrated in
preliminary experiments which showed that premixing the
diluted antisera with their respective antigens (10 g/ml puri-
fied recombinant IGFBP-3, -4, or -5, Upstate Biotechnology)
completely blocked cartilage staining (not shown). After sev-
eral PBS washes the slides were mounted and coverslipped
and images (512×512 pixels) of each stained section were
taken using a Biorad/Nikon laser scanning confocal micro-scope. A 20× objective was used to take four sets of images
for semiquantitative analysis. Two sets of images included
the cartilage surface and extended into the transitional zone
while the second two sets of images included the deep zone.
An excitation wavelength of 488 nm and a 515 nm cut-off
filter was used to image Cy2 (fibronectin, type VI collagen,
tenascin-C) and an excitation wavelength of 630 nm with a
cut-off of 670 nm was used for Cy5 (IGFBP-3,-4,-5) on the
same section. Paired images representing Cy5/Cy2 double
stains for IGFBPs and fibronectin, IGFBPs and tenascin-C,
or IGFBPs and type VI collagen, were used for quantitative
image analysis. The images were first thresholded to deter-
mine the area (pixels2) stained by each antibody (Scion
Image). The extent of overlap between individual stains was
then determined using Boolean functions ‘and’ (the double-
stained area) and ‘or’ (the total area stained by both anti-
bodies). The ratios of ‘and’ areas to ‘or’ areas, which
represent the extent of co-localization between two stains,
were calculated for each set of images. Such ‘and’:‘or’ co-
localization ratios were determined for all five individual
samples. These data were pooled to obtain mean ratios for
each pair of IGFBP/matrix stains and the means analysed by
two-way analysis of variance. Pair-wise comparisons be-
tween the means (e.g. IGFBP-3:fibronectin vs IGFBP-3:type
VI collagen) were performed using the Tukey test.
Three-dimensional, high magnification confocal micro-
scope images were taken to investigate the apparent
co-localization of IGFBP-3 and fibronectin in greater detail.
The sections were mounted as described above and
imaged using a 63× oil immersion objective. Three-
dimensional z-series were generated by taking images at
1.0 m intervals through the thickness of the sections.
These were reassembled into a single projection using
Metamorph software and a personal computer. Two such
projections representing fibronectin and IGFBP-3 staining
of a single sample (67-year-old) are shown in Fig. 2.
A diffusion assay was developed to study interactions of
selected ECM proteins with IGFBP-3. Purified proteins
(200 nM) including bovine plasma fibronectin (ICN), human
collagen type VI (Chemicon), bovine heparan sulfate pro-
teoglycan (HSPG) (Sigma), and human tenascin-C
(Chemicon) were mixed with molten low-melt agarose (1%
agarose in DMEM/10 mM HEPES). Purified IGFBP-3 at
200 nM (R&D Systems) was added and multiple 10 l
aliquots of molten agarose were dotted on culture dishes
and allowed to solidify. The agarose dots were pre-
incubated in a humidified chamber for 1 h at 37°C to allow
intermolecular protein binding to occur. The dots were then
overlain with 100 l DMEM and incubated at room tem-
perature. The medium was removed at various time points
(1, 5, 10, 20, 30, 60, 120, and 180 min) and mixed with an
equal volume of urea extraction buffer (7.7 M urea, 50 mM
sodium acetate, 1.0 mM EDTA, 0.5% CHAPS, pH 6.0).
Agarose dots were extracted overnight in 200 l urea
buffer. Aliquots of the medium and agarose extracts were
serially diluted in urea buffer and applied to Immobilon P
(Millipore) membranes using a vacuum dot blot apparatus
(BioRad). A standard curve was generated by serial dilution
of the purified IGFBP-3 stock. After blotting the membranes
were equilibrated in 50 mM Tris-HCl pH 8.0, 150 mM NaCl,
0.05% Tween 20 (TBST), and blocked in TBST with 5%
non-fat dried milk for 30–60 min. The membranes were
probed overnight at 4°C with a monoclonal antibody to
human IGFBP-3 (Diagnostic Systems Laboratory) diluted
1:10 000 in TBST/5% milk as described by the supplier.
The membranes were washed in TBST and blocked in
TBST/5% milk with 10% normal goat serum (Sigma) formechanism for controlling local IGF-I levels and activity22.
Although ECM-IGFBP interactions have not been
described in articular cartilage, ECM molecules enriched in
the chondrocyte pericellular/territorial matrix could play an
important role in forming complexes with IGFBPs.
Tenascin-C, type VI collagen and fibronectin are compo-
nents of the articular cartilage pericellular/territorial matrix
and all of these molecules have been shown to affect cell
adhesion and cell-matrix interactions38–44. We hypoth-
esized that one or more of these pericellular/territorial
ECM molecules binds IGFBPs. To test this hypothesis we
used immunohistology to compare the spatial distribution
of IGFBP-3, -4, and -5 with the spatial distributions of
fibronectin, tenascin-C, and type VI collagen in human tibial
plateau cartilage. Physical interactions between purified
IGFBP-3 and purified fibronectin, tenascin-C, and type VI
collagen were tested in an agarose diffusion assay.
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phosphate-conjugated antibody (Promega) diluted
1:10 000 in secondary blocking buffer. Alkaline phos-
phatase activity was detected by chemiluminescence using
the CDP-Star substrate according to the manufacturer’s
directions (Roche). Pre-flashed Kodak XR-mat film was
exposed to the membranes for 5–15 min to record the
chemiluminescent signals. The developed films were elec-
tronically scanned using a Scanjet IICX scanner (Hewlett
Packard). The images were analysed using Scion Image
software on a personal computer. Standard curve data for
each blot were plotted and the regression lines used to
calculate IGFBP-3 in the agarose and medium extracts at
each time point. The percentage of total IGFBP-3 remain-
ing in the agarose dot at each time point (IGFBP-3 agarose/
IGFBP-3 agarose+medium) was calculated. These
percentages were plotted as function of time and the data
were fitted with exponential decay curves (Microcal Origin)
to determine the t1/2 for protein retention in the agarose dot.
The statistical significance of differences in t1/2 between
IGFBP-3 alone and IGFBP in the presence of different
matrix proteins was determined using one-way analysis of
variance with the Tukey test for multiple comparisons.Fig. 1. Cartilage morphology and sampling scheme for immunolo-
calization analysis. A low-magnification polarized light image of a
typical cartilage section is shown at the top of the figure. The
section is oriented with the cartilage surface on the right and the
tidemark on the left. Black outlined boxes represent the approxi-
mate areas and locations of the superficial and deep zone areas
used for image analysis. The two smaller polarized light micro-
graphs on the bottom of the figure show the morphology of the
deep zone tissue (left) and superficial zone tissue (right) at the
magnification used for fluorescence image analysis.Results
Full-depth cartilage sections were stained using indirect
immunofluorescence with a panel of antibodies directed
against matrix components and IGF-I binding proteins.
Figure 1 shows a typical section viewed under polarizedlight and shows the approximate areas and locations of the
superficial and deep zones sampled for image analysis
(outlined boxes). The appearance of the tissue at the
magnification used for these analyses is shown in the two
polarized light micrographs at the bottom of Fig. 1. Immu-
nolocalization studies at low magnification (4× objective)
showed that although IGFBP-3, fibronectin, type VI colla-
gen, and tenascin-C were enriched in the pericellar/
territorial matrix their overall tissue distribution differed:
type VI collagen was abundant around chondrocytes from
the superficial through the deep zone while fibronectin was
most abundant below the superficial zone and tenascin-C
was abundant only within the superficial zone. (not shown).
Images of IGFBP/matrix protein double stains taken at
higher magnification (20× objective) revealed striking dif-
ferences in the distributions of different IGFBPs and their
co-localization with individual matrix proteins. IGFBP-3
staining was most intense in the transitional and deep
zones, extending from the pericellular to the territorial
matrix around chondrocytes. In contrast, IGFBP-4, and -5
were present in all zones and were confined primarily to the
pericellular matrix. These stains were generally less
intense than staining for IGFBP-3, consistent with pub-
lished studies which showed that IGFBP-3 is expressed
at higher levels by human chondrocytes than IGFBP-4 or
-5 cartilage9. Examples of typical immunofluorescence
images are presented in Fig. 2. The color panel in Fig. 2(a)
illustrates the appearance of IGFBP-3/matrix double stains
on sections of cartilage from the 67-year-old donor. Images
of IGFBP-4, and -5/matrix double stains were omitted for
clarity. Each series of color images in Fig. 2(a) shows
staining results for matrix proteins on the left (green) and
IGFBP-3 in the middle (red). Overlays of the matrix/
IGFBP-3 stains are shown on the right (red, green, yellow).
Yellow areas in the overlay indicate coincidence of the
green (matrix) and red (IGFBP-3) stains. All examples are
transitional/deep zone images with the exception of C,
which includes superficial tenascin-C staining. Simple
inspection of the IGFBP-3/fibronectin overlay [a, right],
where broad yellow areas are readily apparent, suggests
that IGFBP-3 co-localized extensively with fibronectin. The
paucity of yellow highlights in the IGFBP-3/type VI collagen
overlay [b, right], and IGFBP-3/tenascin-C overlay [c, right]
indicate that IGFBP-3 co-localized with these proteins to a
much lesser degree than with fibronectin. The left column
of the black and white panel in Fig. 2(b) shows single
antibody staining patterns for IGFBP-3 (a), -4 (b), and -5
(c). The adjacent images show negative controls in which
the anti-IGFBP antibodies were applied in the presence of
excess antigens, reducing binding to background levels.
These results indicated that the staining patterns were
antigen-specific. Additional negative controls in which nor-
mal rabbit serum was substituted for the polyclonal anti-
bodies revealed similar low background levels. Isotype
controls in which mouse IgG2 antibodies were substituted
for anti-matrix monoclonal antibodies were also negative
(not shown).
The co-localization of fibronectin with IGFBP-3 was
investigated in greater detail using higher magnification
and three-dimensional reconstruction techniques. Sites
were selected for this analysis from areas where
co-localization was striking at low magnification. Multiple
images in the z-plane were collected and used to generate
three-dimensional images of an IGFBP-3 and fibronectin
double-stained section. Three such reconstructions were
performed using different samples. In all three cases we
found precise three-dimensional co-localization of the two
Osteoarthritis and Cartilage Vol. 10, No. 7 559Fig. 2. Immunolocalization of IGFBP-3 and matrix proteins in cartilage. (a) Three series of scanning confocal images show double-
fluorescence stained cartilage cryosections. (A) Fibronectin (green) and IGFBP-3 (red); (B) type VI collagen (green) and IGFBP-3 (red); (C)
tenascin-C (green) and IGFBP-3 (red). Right panels are overlays which highlight areas stained by both antibodies in yellow. The large
yellow-highlighted areas in series A indicate that fibronectin and IGFBP-3 are extensively co-localized. (b) Confocal images on the left show
single fluorescence staining for IGFBP-3 (A); IGFBP-4 (B) and IGFBP-5 (C). Right panels show confocal micrographs of negative controls
in which antibodies were mixed with purified IGFBP-3, -4, or -5.Fig. 3. Fibronectin and IGFBP-3 around a single chondrocyte. Three-dimensional reconstruction of a single cell from a cartilage cryosection
double-stained for fibronectin (FN) and IGFBP-3 (BP-3). The images shown were reconstructed from optical sections taken at 1 m intervals
in the z-plane using a 63× objective. The similar distributions of fluorescence signals around the dark cell center is apparent.stains around single chondrocytes as shown in Fig. 3,
which represents sections from the 67-year-old sample.
Quantitative image analysis of double-stained cartilage
sections was used to compare IGFBP/matrix co-
localization. Co-localization ratios were determined for
each set of images by measuring the areas stained by both
antibodies (overlapping areas) divided by the areas stained
by either antibody (total area) in the same 20× microscope
field. The system was validated as follows: first, we con-
firmed that analysis of pairs of identical images returned theexpected co-localization ratio of 100% for perfectly overlap-
ping stains; second, we confirmed that when pixel values of
one of these identical images were inverted prior to analy-
sis, the system gave the anticipated 0% ratio for perfectly
non-overlapping stains; third, we confirmed that analysis of
random pairs of images (images from different microscopic
fields) gave a low co-localization ‘background’ of
1.6%±2.6% (N=9) for both IGFBP-3 and fibronectin stains.
Sample co-localization ratios were determined for all pair-
wise combinations of individual IGFBPs with individual
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the cartilage samples by imaging four fields per sample.
Two images included the cartilage surface and extended
into the transitional zone while the remaining two fields
included the transitional zone and extended into the deep
zone. Means and standard deviations based on data
pooled from five different osteoarthritic samples (N=20)
and four different non-osteoarthritic samples (N=16) are
shown in Fig. 4. IGFBP-3, IGFBP-4, and IGFBP-5 in the
osteoarthritic samples co-localized to some degree with
tenascin-C, and type VI collagen; however, these areas
were always <15% of the total stained area and no statisti-
cally significant differences were observed among the
means. IGFBP-4 and IGFBP-5 and fibronectin showed low,
near background co-localization levels (≤5%); however,
IGFBP-3/fibronectin ratios, which ranged from 2% to 75%,
were much higher on average (∼38%) than any other
IGFBP/matrix pairs we tested. This mean 38% ratio was
lower than the 100% obtained by analysing identical
images, indicating that IGFBP-3/fibronectin co-localization
is not complete, however, the data clearly show that
IGFBP-3 was much more likely co-localize with fibro-
nectin than were other IGFBPs. Indeed, despite the largestandard deviations associated with sample-to-sample
variation, the mean IGFBP-3/fibronectin ratio was signifi-
cantly greater (P<0.05) than the IGFBP-4/fibronectin and
the IGFBP-5/fibronectin ratios. Moreover, the IGFBP-3/
fibronectin ratio was significantly greater than either the
IGFBP-3/type VI collagen ratio or the IGFBP-3/tenascin-C
ratio. Analysis of the four non-osteoarthritic samples
revealed a similar co-localization pattern: The mean
IGFBP-3/fibronectin ratio (40%) was again significantly
greater than the ratios for IGFBP-4/fibronectin (7.2%) and
IGFBP-5/fibronectin (16%) (P<0.05) and significantly
greater than the ratios for IGFBP-3/type VI collagen and
IGFBP-3/tenascin (P<0.05). Together these data support
the conclusion that the tissue distributions of fibronectin
and IGFBP-3 overlap to similar extent in both osteoarthritic
and non-osteoarthritic human cartilage.
Binding studies were performed to determine if the
immunohistological co-localization of IGFBP-3 with
fibronectin may be due to a physical interaction between
the two proteins. Binding between IGFBP-3 and purified
matrix proteins was tested using a diffusion assay in which
different matrix proteins were mixed in agarose with
IGFBP-3. The solidified agarose mixture was then overlain
with liquid medium and the diffusion of IGFBP-3 into the
medium measured as a function of time. The assay is
based on the principle that the diffusion rate of macromol-
ecules through the agarose gel depends on molecular size:
under the conditions of the assay, the relatively large
intermolecular complexes formed by IGFBP-3-matrix bind-
ing diffuse more slowly in agarose than does IGFBP-3
alone, thus, intermolecular binding results in slower release
of IGFBP-3 into the medium. An example of the immuno-
blots used to quantitate IGFBP-3 in the medium and
agarose is shown in Fig. 5(a). The ratios of agarose-
retained to total IGFBP-3 were plotted as a function of time.
The typical plot shown in Fig. 5(b) shows the time-
dependent decline in agarose retention from 0 to 60 min
and the increased retention observed in the presence of
specific matrix proteins. Such plots were fitted with expo-
nential decay curves to determine t1/2 for IGFBP-3 retention
in agarose alone and in agarose containing fibronectin,
tenascin, type VI collagen, or heparan sulfate proteoglycan.
These data are summarized in the histogram in Fig. 6,
which shows the effects of matrix protein addition on t1/2.
The t1/2 for IGFBP-3 alone was 42 min±18 min (standard
deviation). The addition of heparan sulfate proteoglycan
significantly extended t1/2 to 149 min±54 min (P<0.05).
Fibronectin had similar effects, significantly extending t1/2
to 107±39 min. In contrast neither tenascin-C nor type VI
collagen had significant effects on IGFBP-3 retention.
These results confirm the potential for physical interaction
between IGFBP-3 and fibronectin in the cartilage extra-
cellular matrix.Fig. 4. Co-localization ratios for IGFBPs and matrix proteins.
Double-stained cartilage sections were analysed to determine the
ratio of the areas staining for both IGFBPs and matrix proteins to
the total area stained by both antibodies (co-localization ratio). The
data represent the means and standard deviations (error bars) for
samples from five osteoarthritic tibial plateaus (a) and four non-
osteoarthritic tibial plateaus (b). The IGFBP-3/fibronectin ratio was
significantly greater than the ratios for IGFBP-3/type VI collagen,
or IGFBP-3/tenascin-C, and greater than the ratios for IGFBP-4/
fibronectin, or IGFBP-5/fibronectin for both normal and osteoar-
thritic samples (P<0.05).Discussion
We hypothesized that one or more components of the
chondrocyte-associated ECM bind IGFBPs. We suspected
that articular cartilage ECM components that concentrate in
the matrix near chondrocytes, and that can effect cell matrix
interactions, would be the most likely molecules to bind
IGFPBs. Fibronectin, tenascin-C and type VI collagen meet
these criteria. Immunolocalization studies showed that
IGFBP-3 co-localized with fibronectin in the pericellular/
territorial matrix of the middle and deep zones of both
osteoarthritic and non-osteoarthritic articular cartilage, but
Osteoarthritis and Cartilage Vol. 10, No. 7 561Fig. 5. Agarose diffusion assay. (a) Autoradiogram showing typical
results of IGFBP-3 immunoassay of medium and agarose extracts
containing purified IGFBP-3. (b) Plot of agarose/agarose+medium
IGFBP-3 ratios at time points from 0–60 min. IGFBP-3 in agarose
alone (h) or in the presence of fibronectin (_), or heparan sulfate
proteoglycan (C).Fig. 6. Effects of extracellular matrix molecules on IGFBP-3
retention in agarose. Columns and error bars show mean t1/2 and
standard deviations based on at least three assays. Values are for
IGFBP-3 retention in the absence (BP=IGFBP alone), presence of
matrix molecules (+Fn =IGFBP-3+fibronectin), (+VI=IGFBP-
3+type VI collagen), (+HSPG=IGFBP-3+heparan sulfate proteo-
glycan). t1/2 was significantly increased (P<0.05) with the addition
of fibronectin and HSPG, but not with tenascin or type VI collagen.did not co-localize with tenascin-C or type VI collagen.
Although the ∼40% mean co-localization ratio for
fibronectin-IGFBP-3 indicated that the two stains were not
perfectly overlapping, high resolution studies of three sites
where co-localization was striking at low resolution indi-
cated that IGFBP-3 and fibronectin overlapped precisely in
these selected areas. The distributions of other cartilageIGFBPs, including IGFBP-4, and -5, failed to show a
correlation with any of the matrix proteins we examined.
These observations suggested that specific IGFBP-3-
fibronectin interactions occur in the cartilage matrix. The
potential for such an interaction was demonstrated using
purified proteins in an agarose diffusion assay. The diffu-
sion assay is essentially a solution binding experiment
which separates matrix-bound from free IGFBP-3 on the
basis of the increased molecular size of IGFBP-3-matrix
complexes which are trapped in the agarose gel. This
approach avoids the high background problems encoun-
tered in solid-phase binding assays which are caused by
the strong tendency of IGFBP-3 to stick to plastics even in
the presence of non-ionic detergents and blocking agents
such as BSA or gelatin. The diffusion assay revealed that
heparan sulfate proteoglycan, which has been shown to
bind IGFBP-345, slowed IGFBP-3 diffusion out of agarose.
Fibronectin also significantly retarded IGFBP-3 diffusion
but neither type VI collagen nor tenascin-C were effective.
Taken together, the immunolocalization and diffusion assay
results strongly support the hypothesis that fibronectin and
IGFBP-3 are physically associated in the cartilage extra-
cellular matrix. Additional support comes from a recently
published study in which fibronectin-IGFBP-3 interaction
was observed in a yeast two-hybrid screening of a human
placental cDNA library. This study identified fibronectin as
one of 53 clones encoding IGFBP-3-binding proteins46.
Fibronectin is a component of the extracellular matrices
of all fibrous connective tissues. This non-collagenous
glycoprotein promotes the adhesion and migration of fibro-
blasts in vitro and it may have an important role in the repair
of fibrous vascularized connective tissues. Although
fibronectin isoforms are known components of articular
cartilage extracellular matrix, their functions and potential
functions in this non-vascularized tissue have not been
defined47–50. In vitro studies show that fibronectin has
a number of direct effects on chondrocytes: adding
fibronectin to chondrocyte cultures promotes substrate
attachment, spreading and flattening of the cells, reorganiz-
ation of intracellular actin into stress fibers and formation of
focal adhesions. These effects are associated with loss
of the chondrocyte phenotype38. High concentrations of
fibronectin fragments which are present in osteoarthritic
cartilage have been shown to induce chondrocyte catabolic
activity, but low concentrations may stimulate matrix
synthesis51–53. Intact fibronectin blocks the anabolic effect
of IGF-I on chondrocytes maintained in a flattened form in
monolayer cultures, but stimulates chondrocyte incorpor-
ation of sulfate and enhances the effect of IGF-I when
chondrocytes are maintained in a spherical form in alginate
cultures54. This later observation suggests that fibronectin
may have a role in maintaining or repairing articular
cartilage. Fibronectin also has been shown to interact with
the articular cartilage ECM proteoglycan decorin, which
binds the growth factor TGF- an interaction that could help
regulate the chondrocyte response to TGF- and create
reservoirs of TGF- in the matrix55.
The current study suggests that another function of
articular cartilage fibronectin is localizing IGFBP-3 in the
matrix near chondrocytes. IGF-I stored in the cartilage
ECM by binding to IGFBP 3 could act as a slow-release
reservoir, preventing rapid fluctuations in local IGF-I con-
centration due to changes in IGF-I synthesis rates or other
factors. This arrangement would prevent inappropriate
stimulation of matrix synthesis or transient dips in IGF-I
levels below concentrations needed to maintain chondro-
cyte viability and anabolic activity. Stored IGF-I may be
562 J. A. Martin et al.: Protein 3 and fibronectin in human articular cartilagerapidly released by IGFBP proteolysis when matrix degra-
dation increases the demand for new ECM synthesis31–34.
This study demonstrates a striking spatial association
between fibronectin and IGFPB-3, but has important limi-
tations. Although we felt that our hypothesis demanded an
immunohistological approach, there are a number of poten-
tial difficulties with quantitation and interpretation of these
data. Based on antigen competition studies and isotype
controls we are confident that the staining patterns we
observed are specific, however, relative differences in the
sensitivity of the stains may have led us to over- or
underestimate co-localization.
Overall the results of this study suggest that human
articular cartilage fibronectin interacts with IFGPB-3 in the
chondrocyte-associated matrix to create complexes con-
taining fibronectin, IGFPB-3 and IGF-I. These complexes
could have important roles in maintaining and repairing
articular cartilage. Further work is needed to determine how
these interactions influence chondrocyte responses to
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